DURECT Corporation

DURECT Corporation develops medicines based on its epigenetic regulator program. The companys lead product, larsucosterol (DUR-928), is in Phase IIb clinical trial for treating alcohol-associated hepatitis and nonalcoholic steatohepatitis. They also offer ALZET products for research animal studies. Additionally, they market POSIMIR for post-surgical pain relief and Methydur for attention deficit hyperactivity disorder. The company has agreements with Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Innocoll Pharmaceuticals Limited. DURECT was incorporated in 1998 and is headquartered in Cupertino, California.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

0.6 USD

Potential

-100%

Strengths

Price to book ratio (1.95) is lower than the sector mean (733.70).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0